FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952577661> ?p ?o ?g. }

• W2952577661 endingPage "109" @default.
• W2952577661 startingPage "105" @default.
• W2952577661 abstract "Over the past two decades, several new agents have been approved by regulatory agencies for the treatment of different types of lymphoid malignancies.1 Within non-Hodgkin's lymphoma (NHL), most new agents were approved for follicular B cell lymphoma. In contrast, only two drugs have been approved for relapsed diffuse large B cell lymphoma in more than three decades. In many cases, approved drugs targeted unique molecular mechanism, in other cases, several agents were approved for targeting the same oncogenic pathway such as the PI3 kinase pathway and BTK. Many other investigational agents targeting intracellular mechanisms are under investigation. A summary of single agent activity of several new agents in patients with diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma is shown in Figure 1. In this review, we will focus on the current status of drug development aiming at new and unique targets. Enhancer of zeste homolog 2 (or EZH2) is the enzymatic subunit that catalyzes the lysine Lys27 methylation of histone H3 (H3K27). EZH2 plays an essential role in germinal center biology.2, 3 EZH2 genetic deletion in mice completely abrogated germinal centers formation. Heterozygous point mutations affecting tyrosine 641 (Y641) within the C-terminal catalytic SET domain of EZH2 have been identified in follicular lymphoma and GCB-DLBCL, with an incidence of approximately 15% to 20% in both tumor types.4, 5 Y641 is a gain-of-function activating mutation, leading to increased levels of H3K27me3 and resulting in suppression of gene expression. In vivo, expression of the gain-of-function mutant allele in GC B cells synergizes with BCL2 protein overexpression and accelerates the development of lymphomas, providing a rationale for the development of drugs aimed at inhibiting EZH2 activity alone or in combination with BCL2 inhibitors. In contrast, EZH2 genetic inactivation (deletion, frameshift, nonsense, and missense mutations) has been identified in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and T-cell acute lymphocytic leukemia. These observations raised the possibility of implicating EZH2 loss-of-function in the development of malignancy. Furthermore, this raised concerns regarding the potential toxicity of long term EZH2 inhibitors. To date, there are two EZH inhibitors in clinical development, one selectively targets EZH2 (tazemetostat, EPZ-6438), and a second inhibits both EZH1 and EZH2 (DS-3201b). In a first-in-man, phase I study of patients with relapsed lymphoma or solid tumors, tazemetostat demonstrated a reasonable safety profile and a promising clinical activity.6 Eight of 21 patients (38%) with B-cell NHL had a major clinical response, including three complete responses. The maximum tolerated dose was not reached, and the recommended phase II dose was determined to be 800 mg twice daily. Objective tumor responses were observed only in solid tumor patients with INI1- or SMARCA4-negative tumors. Tazemetostat was also evaluated in a phase II clinical trial in 156 patients with FL or DLBCL. Patients were stratified based on the presence of EZH2 mutations in their tumors. The highest response rate (71%) was observed in patients with FL that harbored EZH2 mutations. However, clinical responses were also observed in FL and GCB-DLBCL that did not carry the mutations (Figure 1). The most common toxicities, regardless of grade, included fatigue, nausea, cough, diarrhea, and thrombocytopenia. Most recently, a dual EZH 1/2 inhibitor (DS-3201b) was recently evaluated in a phase I clinical trial. DS-3201b demonstrated clinical activity across a range of B-cell and T-cell NHL subtypes, with an overall response rate of 53%. Remarkably, in a small subset of patients with T cell lymphoma, 80% had a major response. Aberrant activation of BCR signaling pathway is implicated in the pathogenesis and progression of a variety of B-cell malignancies. Fostamatinib disodium (R788) was the first agent to target BCR signaling pathway by inhibiting SYK protein. However, initial clinical results were not very encouraging. Subsequently, several agents were developed to target the downstream protein Bruton's tyrosine kinase (BTK). To-date, two BTK inhibitors (ibrutinib and acalabrutinib) have been approved for the treatment of lymphoid malignancies. In NHL, these agents are currently approved only for the treatment of patients with relapsed MCL (Figure 1). The success of BTK inhibitors for the treatment of B cell lymphoid malignancies has generated enthusiasm about the development of other agents that can disrupt different nodes that enhance B-cell receptor signaling. To date, the leading compounds are aimed at targeting IRAK4 and MALT1 (Figure 2). Toll-like receptor (TLR) signaling adaptor protein MYD88 is frequently mutated in a variety of lymphoid malignancies, including Waldenstrom's macroglobulinemia, marginal zone lymphoma, and DLBCL.7 In most of these cases, tumors harboring the L265P mutations are prone to be more sensitive to BTK inhibitors. Interleukin-1 receptor-associated kinase 4 (IRAK4) accounts for almost all of the biological functions of MYD88, making it an attractive therapeutic target for MYD88-driven lymphoid malignancies (Figure 2).8 In one study, small molecule inhibitors of IRAK4 were shown to be toxic against DLBCL lines harboring MYD88 L265P. Mechanistically, IRAK4 inhibition attenuated NF-κB and IL-6/IL-10-JAK-STAT3 signaling pathways. Furthermore, BTK or BCL2 inhibition enhanced the anti-proliferative activity of IRAK4 inhibitors DLBCL xenograft models.9 CA-4948 is a reversible oral kinase inhibitor of IRAK4. CA-4948 demonstrated a dose-dependent efficacy in ABC-DLBCL MYD88 -L265P xenograft tumor models and patient-derived tumors, and it synergized with the anti Bcl-2 inhibitor, venetoclax. A phase I study of the IRAK4 inhibitor CA-4948 is currently being evaluated in patients with relapsed and refractory lymphoma (NCT03328078). In 1999, the MALT1 gene was discovered after a new chromosomal translocation t(11;18)(q21;q21) was identified in cases of MALT (Mucosa associated lymphoid tissue) lymphoma. The C-terminal part of the fusion protein contained a domain homologous to the caspases, and hence defined MALT1 as a “paracaspase.” MALT1 plays a key role in activating B and T lymphocytes, through regulating NF-kB activation.10, 11 The activation of NF-kB pathway is achieved through several mechanisms, including recruiting TRAF6 and cleavage of the negative regulator TNFAIP3 (A20) (Figure 2). Accordingly, MALT1 is an attractive target for the treatment of NF-kB driven lymphomas, especially DLBCL of the ABC subtype.12, 13 In preclinical testing, MI-2, a covalent inhibitor of MALT1, and mepazine and thioridazine, which are reversible MALT1 inhibitors, demonstrated promising clinical activity against ABC-DLBCL in vitro and in mouse models. Other MALT1 inhibitors are also under development. Although no MALT1 inhibitor is currently in clinical testing, both Janssen and Abbvie plan to conduct clinical trials of MALT1 inhibitors in patients with relapsed lymphoma. The B-cell lymphoma 2 (BCL2) protein family, a key regulator of cell survival and death, is comprised of three functionally distinct subgroups: (1) the anti-apoptotic proteins (BCL2, BCL-XL, BCL-W, MCL1, A1/BFL-1), (2) the pro-apoptotic effector proteins (BAX and BAK), and (3) the pro-apoptotic BH3-only proteins (BIM, PUMA, BID, BAD, BIK, BMF, NOXA, HRK). Pharmacologic inhibition of the anti-apoptotic proteins can be achieved through the use of small molecules that mimic BH3 domain. These BH3-mimetics, bind to BCL2 or MCL1, leading to the release of pro-apoptotic proteins and triggering apoptosis. The first BH3 mimetic drug to be approved by regulatory agencies is venetoclax, a BCL2 selective oral inhibitor. The MCL1 gene is frequently amplified in human cancers, and its protein overexpression is observed in a variety of tumors, including multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, among others. Mcl-1 can mediate resistance to several cytotoxic agents and to the Bcl-2 selective inhibitor venetoclax.14 Several Mcl-1 selective inhibitors are currently under clinical development for the treatment of cancer. AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development.15 AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, by activating the Bak-dependent mitochondrial apoptotic pathway of AZD5991 is currently being evaluated in a phase I clinical trial in patients with hematological malignancies (NCT03218683). S63845 is a selective, BH3 mimetic MCL1 inhibitor with no appreciable binding to BCL-2 or BCL-XL.16 S63845 binds to the BH3-binding groove of human MCL1 with a Kd of 0.19 nM. S63845 potently killed MCL1-dependent cell lines in vitro and in xenograft mouse models. Interestingly, S63845 showed potent cytotoxic activity against c-MYC-driven human Burkitt lymphoma cell lines. A phase I clinical trial is currently evaluating the safety and efficacy of S63845 in patients with leukemia (NCT02979366). A third compound, AMG 176, is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid apoptosis in vitro in a variety of hematologic malignancies.17 A phase I study is currently evaluating AMG 176 in patients with relapsed multiple myeloma and leukemia (NCT02675452). Arginine methylation is a posttranslational modification catalyzed by protein arginine methyltransferases (PRMTs). PRMTs catalyze the mono or dimethylation of arginine residues on histone and non-histone proteins. Aberrant expression or functional dysregulation of PRMTs is associated with various disease states, including cancer.18 Currently, nine members of PRMTs have been identified in human cells. PRMT5 is a type II PRMT that specifically catalyzes symmetric dimethylation of arginine residues on H3 or H4. PRMT5 regulates transcriptional repression, RNA splicing, and signal transduction. PRMT5 is upregulated in a variety of cancers, including lymphoma. PRMT5 has been shown to play an important role in lymphomagenesis, controlling the growth of transformed B cells. The precise mechanisms involved in PRMT5 oncogenic activity are poorly described. However, some mechanisms have been recently identified, including arginine methylation of the tumor suppressor p53, that inhibits p53-mediated apoptosis.19 Furthermore, PRMT5 supports constitutive CYCLIN D1/CDK4/6 activity leading to inactivation of the RBL2/E2F tumor suppressor pathway (8). Collectively, these data suggested that targeting PRMT5 may have a therapeutic value in a variety of cancers, including lymphoma. PRMT5 overexpression has been observed in mantle cell lymphoma (MCL). In turn, PRMT5 inhibition has been shown to inhibit proliferation and/or induce cell death in MCL cell lines.20 In most cases, wild type P53 was required for optimal anti-lymphoma activity of PRMT5 inhibitors. To date, at least one PRMT5 inhibitor (GSK3326595) is currently being investigated in patients with relapsed solid tumors and NHL (NCT02783300). This work is partially supported by NIH P50 CA192937 (MSK Lymphoma SPORE), the Leukemia and Lymphoma Society of America SCOR grant 7014-17, and by the NCI Cancer Center Support Grant (P30 CA008748)," @default.
• W2952577661 created "2019-06-27" @default.
• W2952577661 creator A5068152076 @default.
• W2952577661 date "2019-06-01" @default.
• W2952577661 modified "2023-10-16" @default.
• W2952577661 title "New drugs for new targets in lymphoma" @default.
• W2952577661 cites W1992915563 @default.
• W2952577661 cites W1996699413 @default.
• W2952577661 cites W2009087895 @default.
• W2952577661 cites W2063948662 @default.
• W2952577661 cites W2071576183 @default.
• W2952577661 cites W2116382435 @default.
• W2952577661 cites W2137003359 @default.
• W2952577661 cites W2139792086 @default.
• W2952577661 cites W2168135773 @default.
• W2952577661 cites W2201804574 @default.
• W2952577661 cites W2212076220 @default.
• W2952577661 cites W2322587683 @default.
• W2952577661 cites W2345827275 @default.
• W2952577661 cites W2534349779 @default.
• W2952577661 cites W2562093910 @default.
• W2952577661 cites W2797292560 @default.
• W2952577661 cites W2808005169 @default.
• W2952577661 cites W2892573863 @default.
• W2952577661 cites W2900113415 @default.
• W2952577661 cites W2905070646 @default.
• W2952577661 doi "https://doi.org/10.1002/hon.2592" @default.
• W2952577661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6570411" @default.
• W2952577661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31187529" @default.
• W2952577661 hasPublicationYear "2019" @default.
• W2952577661 type Work @default.
• W2952577661 sameAs 2952577661 @default.
• W2952577661 citedByCount "1" @default.
• W2952577661 countsByYear W29525776612022 @default.
• W2952577661 crossrefType "journal-article" @default.
• W2952577661 hasAuthorship W2952577661A5068152076 @default.
• W2952577661 hasBestOaLocation W29525776612 @default.
• W2952577661 hasConcept C126322002 @default.
• W2952577661 hasConcept C2779338263 @default.
• W2952577661 hasConcept C71924100 @default.
• W2952577661 hasConceptScore W2952577661C126322002 @default.
• W2952577661 hasConceptScore W2952577661C2779338263 @default.
• W2952577661 hasConceptScore W2952577661C71924100 @default.
• W2952577661 hasIssue "S1" @default.
• W2952577661 hasLocation W29525776611 @default.
• W2952577661 hasLocation W29525776612 @default.
• W2952577661 hasLocation W29525776613 @default.
• W2952577661 hasLocation W29525776614 @default.
• W2952577661 hasOpenAccess W2952577661 @default.
• W2952577661 hasPrimaryLocation W29525776611 @default.
• W2952577661 hasRelatedWork W1506200166 @default.
• W2952577661 hasRelatedWork W1995515455 @default.
• W2952577661 hasRelatedWork W2048182022 @default.
• W2952577661 hasRelatedWork W2080531066 @default.
• W2952577661 hasRelatedWork W2604872355 @default.
• W2952577661 hasRelatedWork W2748952813 @default.
• W2952577661 hasRelatedWork W2899084033 @default.
• W2952577661 hasRelatedWork W3031052312 @default.
• W2952577661 hasRelatedWork W3032375762 @default.
• W2952577661 hasRelatedWork W3108674512 @default.
• W2952577661 hasVolume "37" @default.
• W2952577661 isParatext "false" @default.
• W2952577661 isRetracted "false" @default.
• W2952577661 magId "2952577661" @default.
• W2952577661 workType "article" @default.